Topical dutasteride with microneedling in treatment of male androgenetic alopecia

1. Muller DC, Giles GG, Sinclair R, Hopper JL, English DR: Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013; 22(2): 209-15.

2. Hunt N and Mchale S: The psychological impact of alopecia. BMJ. 2005; 331(7522): 951-3.

3. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M: A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014; 70(3): 489-498.e3.

4. Kim MW, Shin IS, Yoon HS, Cho S and Park HS: Lipid profile in patients with androgenetic alopecia: a meta-analysis. J Eur Acad Dermatol Venereol. 2017; 31(6): 942-951.

5. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D and Kouskoukis K: Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014; 7(4): 213-9.

6. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A: A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013; 5(1): 6-11.

7. Arif T, Dorjay K, Adil M and Sami M: Dutasteride in Androgenetic Alopecia: An Update. Curr Clin Pharmacol. 2017; 12(1): 31-35.

8. Abdallah M, El-Zawahry K and Besar H: Mesotherapy using dutasteride-containing solution in male pattern hair loss: A controlled pilot study. J Pan Arab Leag Dermatol. 2009; 20: 137-45.

9. Sobhy N, Aly H, El Shafee A and El Deeb M: Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013; 4(1): 40-5.

10. Saceda-Corralo D, Rodrigues-Barata AR, Vano-Galvan S and Jaen-Olasolo P: Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017; 9(3): 143-145.

11. Fertig RM and Gamret AC: Microneedling for the treatment of hair loss? 2017.

12. Dhurat R and Mathapati S: Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy. Indian J Dermatol. 2015; 60(3): 260-3.

13. Shapiro J, Wiseman M and Lui H: Practical management of hair loss. Can Fam Physician. 2000; 46: 1469-77.

14. Sehgal VN, Kak R, Aggarwal A, Srivastava G and Rajput P: Male pattern androgenetic alopecia in an Indian context: a perspective study. J Eur Acad Dermatol Venereol. 2007; 21(4): 473-9.

15. Barber B, Kaufman K, Kozloff R, Girman C and Guess H: A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat. 1998; 9(3): 181-186.

16. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I: A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004; 50(4): 541-53.

17. Mounsey AL and Reed SW: Diagnosing and treating hair loss. Am Fam Physician. 2009; 80(4): 356-62.

18. Andriole GL and Kirby R: Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003; 44(1): 82

19. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY: Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010; 63(2): 252-8.

20. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM: The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007; 92(5): 1659-65.

21. Olsen EA: Female pattern hair loss. J Am Acad Dermatol. 2001; 45(3 Suppl): S70-80.